Orsay, France

Ana Pecina-Lopez

This inventor holds 2 USPTO granted patents, plus 1 CIPO patent. Top assignees: Centre National De La Recherche Scientifique, National Institute of Health and Medical Research, Institut Curie. Active years: 2007.


% Patents Active = 100.0


Average Co-Inventor Count = 7.2

ph-index = 2

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2007

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Ana Pecina-Lopez: Innovator in Meiotic Recombination

Introduction

Ana Pecina-Lopez is a prominent inventor based in Orsay, France. She has made significant contributions to the field of genetics, particularly in the area of meiotic recombination. With a total of 2 patents, her work focuses on innovative methods and kits that enhance the rate of recombination in dividing cells.

Latest Patents

Her latest patents include "Methods for inducing targeted stimulation of meiotic recombination and kits for performing said methods." This invention pertains to various methods, kits, molecules, and cells designed to increase the rate of recombination and target recombination in dividing cells. Specifically, it addresses methods and kits aimed at inducing targeted meiotic recombination.

Career Highlights

Ana has worked with esteemed organizations such as the Centre National de la Recherche Scientifique and the National Institute of Health and Medical Research. Her experience in these institutions has allowed her to develop and refine her innovative approaches to genetic research.

Collaborations

Ana has collaborated with notable colleagues, including Alain Nicolas and Minoo Rassoulzadegan. These partnerships have contributed to her success and the advancement of her research.

Conclusion

Ana Pecina-Lopez is a trailblazer in the field of meiotic recombination, with her patents reflecting her commitment to advancing genetic research. Her innovative methods and collaborations continue to impact the scientific community positively.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…